Skip to main content

Home
The Problem
The Solution
About Us
Management
Board of Directors
Contact Us
Press Releases
Site Map

   











  _________________________________________________________________________  ______________________


Developing Novel, Blood-based Multi-protein Tests 


Cardiac Cath "Rule In Rule Out" & MI, Stroke, and Cardiac Death Prediction


Prevencio's value proposition is "Preventing the Preventable" — that is, improving patient outcomes and reducing healthcare costs by preventing unnecessary cardiac procedures and procedure-related side effects, as well as predicting — and hopefully thereby preventing — one year adverse cardiac events, including myocardial infarct (MI), stroke, and cardiovascular death.

 

In the U.S. alone, more than 8 million patients annually enter the Emergency Room (ER) with complaints about chest pain. It is the second most common reason for ER visits in the US. 

 

ER physicians and cardiologists have tests (ECGs and troponins) to diagnose patients who have already had a heart attack. However, frequently these tests are inconclusive. Additionally, many patients experience chest pain due to non-cardiac reasons, including heartburn, esophageal reflux, and other non-life threatening conditions. Unfortunately, these patients may end up in a diagnostic "gray zone" and a significant number receive expensive and dangerous procedures they do not actually need, including cardiac catheterization ("caths") and coronary CT scans.

 

These are the patients who benefit the most from Prevencio's multi-protein HART™ CAD test for obstructive coronary artery disease diagnosis.

 

A​voiding unnecessary cardiac caths and other cardiac testing procedures may save more than $39,000 per patient.​ With more than one million in-patient cardiac caths in the US every year, we spend more than $39 billion annually. Eliminating a small percentage of the needless cardiac caths could amount to billions of dollars in savings. Additionally, ​unneeded cardiac procedures, including cardiac caths, have patient risks, including contrasting dye toxicity, radiation exposure, and death. These types of procedures account for 1.5% of all cancer in the U.S.

 

In addition to the HART™ CAD test for assessing obstructive coronary artery disease (CAD), Prevencio is developing multi-protein tests for predicting — and hopefully thereby preventing — one year adverse cardiac events, including myocardial infarct, stroke, and cardiac death.

 

 

The HART™ tests will be able to improve care and reduce patient risks and costs for cardiac patients and healthcare systems around the world. ​ 

 

 

Prevencio® is the registered trademark of Prevencio, Inc., a Delaware Corporation. Copyright (2016). All rights reserved. Prevencio's products described here are not for sale and have not been cleared by the FDA for commercial sale.

  

 

 


 

​​​​​​The HART™ CAD blood-based tests help differentiate chest pain patients who have obstructive heart disease and need more extensive testing from those patients who safely can be sent home, as well as those patients at risk for one year myocardial infarct, stroke, and cardiac death.